|
|
Post by goyocafe on May 16, 2018 9:28:00 GMT -5
If Dr. Kendall is making comments like Mannkind already has what other BP are still trying to develop (paraphrasing from his interview in March), what in the world can the big players be thinking? Are they really going to leave this to hope and a prayer that Mannkind doesn't make it financially? I find it hard to believe that someone in a backroom in every big player's headquarters isn't taking pencil to paper and trying to determine the value of the next standard of care in meal time insulin and comparing it to the continuing development costs they'll be incurring trying to catch up.
Someone this morning noted Mike's and Dr. Kendall's connections (e.g. how India was won), and you have to think that these same connections are pondering the same thing that Dr. Kendall has already acknowledged by his coming on board.
|
|
|
|
Post by joeypotsandpans on May 16, 2018 9:38:48 GMT -5
If Dr. Kendall is making comments like Mannkind already has what other BP are still trying to develop (paraphrasing from his interview in March), what in the world can the big players be thinking? Are they really going to leave this to a hope and a prayer that Mannkind doesn't make it financially? I find it hard to believe that someone in a backroom in every big player's headquarters isn't taking pencil to paper and trying to determine the value of the next standard of care in meal time insulin and comparing it to the continuing development costs they'll be incurring trying to catch up. Someone this morning noted Mike's and Dr. Kendall's connections (e.g. how India was won), and you have to think that these same connections are pondering the same thing that Dr. Kendall has already acknowledged by his coming on board. Let's take it one step forward, Kendall had a choice, stay with the company that could spend the next 10yrs. trying to develop something that already exists...he most likely decided he didn't want to wait around for that...Again, he turned down the goliath's to team up with David  It's right in front of you people...plain as day, oh yeah let's focus on guidance on a fledgling disruptor bwahahah! |
|
|
|
Post by #NoMoreNeedles on May 16, 2018 9:55:51 GMT -5
Snakeoil didn't see the light, did they? You cannot assume that BP are visionary all the time.
|
|
|
|
Post by kc on May 16, 2018 9:57:54 GMT -5
If Dr. Kendall is making comments like Mannkind already has what other BP are still trying to develop (paraphrasing from his interview in March), what in the world can the big players be thinking? Are they really going to leave this to a hope and a prayer that Mannkind doesn't make it financially? I find it hard to believe that someone in a backroom in every big player's headquarters isn't taking pencil to paper and trying to determine the value of the next standard of care in meal time insulin and comparing it to the continuing development costs they'll be incurring trying to catch up. Someone this morning noted Mike's and Dr. Kendall's connections (e.g. how India was won), and you have to think that these same connections are pondering the same thing that Dr. Kendall has already acknowledged by his coming on board. Let's take it one step forward, Kendall had a choice, stay with the company that could spend the next 10yrs. trying to develop something that already exists...he most likely decided he didn't want to wait around for that...Again, he turned down the goliath's to team up with David It's right in front of you people...plain as day, oh yeah let's focus on guidance on a fledgling disruptor bwahahah! JOEY,
I agree with you..... Great photo last night of you Inhaling..... To good health....
|
|
|
|
Post by digger on May 16, 2018 10:06:11 GMT -5
If Dr. Kendall is making comments like Mannkind already has what other BP are still trying to develop (paraphrasing from his interview in March), what in the world can the big players be thinking? Are they really going to leave this to hope and a prayer that Mannkind doesn't make it financially? I find it hard to believe that someone in a backroom in every big player's headquarters isn't taking pencil to paper and trying to determine the value of the next standard of care in meal time insulin and comparing it to the continuing development costs they'll be incurring trying to catch up. Someone this morning noted Mike's and Dr. Kendall's connections (e.g. how India was won), and you have to think that these same connections are pondering the same thing that Dr. Kendall has already acknowledged by his coming on board. What I'd like to know is why Novo continued with fiasp development, why is Eli Lilly saying "they are starting the late phases of clinical studies on an ultra fast insulin," and why Sanofi threw over afrezza to continue admelog development. I wonder whether they're actually interested in developing an ultrafast insulin or are just worried about expiring patents. |
|
|
|
Post by mnholdem on May 16, 2018 11:03:34 GMT -5
I've said it before" "The science will prevail". Absolutely, the giant competitors are trying to head off Afrezza because they KNOW that the diabetes medical community is beginning to understand the significance of how an ultra-fast insulin can benefit the treatment of diabetes. This is why it's critical for Dr. Kendall to get the science behind Afrezza out there to that same medical community.
IMO, he also needs to elaborate on how fast Afrezza clears and why that virtually eliminates the dangers associated with "stacking" that is common with RAA injected insulin brands. Fiasp (and eventually other prandials) can try to claim Ultra-Fast but they cannot eliminate the tail and, thus, they will never be able to duplicate what Afrezza does, which is to enter the blood stream as a monomer insulin and exit the blood stream in a short time.
CMO Kendall needs to hammer this message home big time and I am of the opinion that he is currently preparing to do just that immediately following the 2018 ADA Scientific Sessions. I wouldn't be surprised to learn that he has already garnered the support of respected diabetes KOLs, who will back him up and begin endorsing Afrezza.
---
History lesson:
Many recall that Exubera inhaled insulin first hit the market, EVERY SINGLE diabetes BP was racing to develop an inhaled insulin of their own. They were scared to death of its potential. Exubera failed for several reasons but, most notably, it did not perform with anywhere near the speed of MannKind's Technosphere Insulin, because it was delivered as a hexamer insulin. The result was that it was only slightly faster than RAA injectables and it still left a long tail.
Afrezza is a completely NEW and revolutionary breakthough and, once again, BPs are racing to duplicate it's attributes. They won't come close, but I expect them to use deceptive marketing (e.g. Fiasp) to mislead the medical community into thinking they are as good as Afrezza.
Frankly, I don't think Dr. Kendall will let them AND I expect that he will gain the support of the ADA/AACE once the science is understood. No RAA insulin will be able to achieve the kind of Time-in-Range and other new measurements that will be superseding the antiquated A1c measurement for diabetes.
|
|
|
|
Post by lakers on May 16, 2018 12:59:23 GMT -5
Most cost effective, Expect articles on
Journal Impact Factor Year
NEJM 72.406 2016
Lancet 47.831 2017
JAMA 44.405 2016
NEJM
is a weekly medical journal published by the Massachusetts Medical Society. It is among the most prestigious peer-reviewed medical journals[1] as well as the oldest continuously published one.
The journal usually has the highest impact factor of the journals of internal medicine. According to the Journal Citation Reports, NEJM had a 2014 impact factor of 55.873,[24] ranking it first of 153 journals in the category "General & Internal Medicine".[25] It was the only journal in the category with an impact factor of more than 50. By comparison, the second and third ranked journals in the category (The Lancet and JAMA) had impact factors of 45.217 and 35.289 respectively.
Lancet
The Lancet is a weekly peer-reviewed general medical journal. It is one of the world's oldest and best known general medical journals.
The Lancet publishes original research articles, review articles ("seminars" and "reviews"), editorials, book reviews, correspondence, as well as news features and case reports.
JAMA
is a peer-reviewed medical journal published 48 times a year by the American Medical Association. It publishes original research, reviews, and editorials covering all aspects of the biomedical sciences.
|
|
It's right in front of you people...plain as day, oh yeah let's focus on guidance on a fledgling disruptor bwahahah! 
